Ofatumumab With High Dose Methylprednisone Followed by Ofatumumab and Alemtuzumab in 17p CLL
Status:
Terminated
Trial end date:
2017-01-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to examine how two separate groups of 17p deletion Chronic
lymphocytic leukemia (CLL) participants respond to sequential treatment with this particular
combination of drugs. The two groups are those participants who have previously received
treatment for their CLL and those who have not yet received any treatment. The combination of
drugs is Ofatumumab and High-Dose Methylprednisolone (HDMP) first followed by Ofatumumab and
Alemtuzumab. All three drugs are FDA approved and have known activity in treating 17p CLL. We
hope that by combining these drugs together in this study, they will have more benefit than
each one alone and that the subjects' CLL will be significantly impacted.
Phase:
Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
GlaxoSmithKline National Comprehensive Cancer Network